Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 307
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT04935294 | Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction | ||
| NCT01919346 | Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation | ||
| NCT00742859 | Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin | ||
| NCT06449001 | Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis | ||
| NCT01399593 | Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization | ||
| NCT03056040 | ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab | ||
| NCT02207725 | A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban | ||
| NCT01488097 | Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency | ||
| NCT01410916 | Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS) | ||
| NCT03406507 | A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria | ||
| NCT01883544 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects | ||
| NCT01770951 | A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT04320602 | Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab | ||
| NCT05578846 | Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics | ||
| NCT00904826 | An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica | ||
| NCT07160608 | Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis | ||
| NCT04889690 | Study of Multiple Doses of Danicopan in Healthy Participants | ||
| NCT03124368 | A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN | ||
| NCT05565092 | Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease | ||
| NCT04952545 | Study of ALXN2050 in Healthy Adult Participants of Japanese Descent | ||
| NCT04609670 | Study of Radiolabeled ALXN2050 in Healthy Adult Males | ||
| NCT04725812 | Complement Regulation to Undo Systemic Harm in Preeclampsia | ||
| NCT01849562 | Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants | ||
| NCT05501717 | Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants | ||
| NCT03748823 | Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab | ||
| NCT05644561 | Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG) | ||
| NCT02531867 | Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan | ||
| NCT05778071 | Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism | ||
| NCT06015750 | Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia | ||
| NCT05884060 | Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones | ||
| NCT05109390 | A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults | ||
| NCT04248465 | An Efficacy and Safety Study of Ravulizumab in ALS Participants | ||
| NCT03920293 | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | ||
| NCT01303952 | Therapy of Chronic Cold Agglutinin Disease With Eculizumab | ||
| NCT01194804 | E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients | ||
| NCT04504825 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) | ||
| NCT01583218 | Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) | ||
| NCT03578146 | Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4) | ||
| NCT02301624 | Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis | ||
| NCT00380159 | Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A | ||
| NCT01522170 | aHUS Observational Long Term Follow-Up | ||
| NCT04195763 | Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa) | ||
| NCT01335165 | Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT00844844 | Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS | ||
| NCT06830798 | Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation | ||
| NCT04925804 | Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) | ||
| NCT06079372 | Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa | ||
| NCT05202145 | Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants | ||
| NCT01106027 | Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant | ||
| NCT03661528 | Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor |
